HLB bioStep Co.,Ltd. (KOSDAQ:278650)

Market Cap	105.08B -45.4%
Revenue (ttm)	71.47B +25.9%
Net Income	-7.70B
EPS	-101.56
Shares Out	84.47M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	254,215
Average Volume	584,834
Open	1,274.00
Previous Close	n/a
Day's Range	1,251.00 - 1,280.00
52-Week Range	1,206.00 - 2,575.00
Beta	0.00
RSI	34.35
Earnings Date	Nov 14, 2025

About HLB bioStep

HLB bioStep Co.,Ltd. provides various test services in South Korea. It offers non clinical CRO services for cancer, bone and brain disease, endocrineand metabolic and eye disease, liver and circulatory system disease, dental and gastrointestinal disease, hair growth, kidney and respiratory disease, painmodel, and skin disease. It also offers representative analysis equipment, veterinary drug development consulting and clinical trial services, and bioanalysis items. The company was formerly known as KNOTUS Co.,Ltd. HLB bioStep Co.,Ltd. was found...

• Industry: Commercial Physical and Biological Research
• Founded: 2012
• Employees: 147
• Stock Exchange: KOSDAQ
• Ticker Symbol: 278650

Financial Performance

In 2024, HLB bioStep's revenue was 58.17 billion, an increase of 10.14% compared to the previous year's 52.81 billion. Losses were -8.56 billion, 5120.8% more than in 2023.